Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RHO Phyto is a branded portfolio of plant-derived medical cannabis formulations developed and marketed by Avicanna. The products contain varying cannabinoid compositions, primarily cannabidiol, delta-9-tetrahydrocannabinol, and in some formulations cannabigerol, and are intended to modulate the endocannabinoid system through cannabinoid receptors to support management of pain, inflammation, sleep disturbance, anxiety, and depression. The franchise includes multiple dosage forms such as oral drops, sublingual sprays, capsules, topical creams, and transdermal gels, and is manufactured to GMP standards for commercial distribution in markets including Canada, the United States, Germany, and Barbados.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RHO Phyto.